EGFR and non-small cell lung carcinoma: AREG knockdown, neutralization with AREG antibodies, and cotreatment with NSCLC-EVs and the epidermal growth factor receptor–tyrosine kinase inhibitor erlotinib reversed EV-induced osteoclast differentiation.